Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
The Wall Street Journal carries a sad story today of what can go wrong when surgeons with insufficient skill, focus, and experience use high-tech equipment to carry out complicated operations.
Filed under: Uncategorized | Tagged: da Vinci, robot, surgery | 1 Comment »
Dan Zenka thinks we should be lighting the White House blue for Prostate Cancer Awareness Week this September. The “New” Prostate Cancer InfoLink agrees. So … read Dan’s blog and then e-mail the President and Mrs. Obama. Your commentator has already sent in his supporting e-mail.
Filed under: Uncategorized | Tagged: awareness | Comments Off
The role of PSA kinetics (i.e., PSA doubling time and PSA velocity) in the early diagnosis of prostate cancer and in the monitoring of patients on active surveillance protocols has been controversial. We now have some more definitive data.
Filed under: Living with Prostate Cancer, Management | Tagged: active surveillance, doubling time, kinetics, PSA, PSADT, PSAV, velocity | 6 Comments »
Following the approval of sipuleucel-T (Provenge) last week, every biopharmaceutical company with a “cancer vaccine” in development appears to have been tooting its horn about the importance of their particular product.
Filed under: Drugs in development | Leave a Comment »
Today’s news reports include comments on studies dealing with: A compound panel of markers for predicting risk for prostate cancer Open vs. robot-assisted radical prostatectomy: urologists’ perceptions Clinically relevant quality of life assessment after first-line therapy A compound panel of markers for predicting overall survival of patients with CRPC
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: castration-resistant prostate cancer, CRPC, kallikrein, open, prognosis, prostatectomy, quality of life, RALP, risk, robot-assisted, survival | Leave a Comment »
A paper in a forthcoming issue of European Urology recommends strongly that clinicians should monitor serum testosterone (serum T) levels during androgen-deprivation therapy (ADT) in men with prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapy, serum, serum T, testosterone | 2 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site